NCT02536300 2023-08-14Dose Optimization Study of Idelalisib in Follicular LymphomaGilead SciencesPhase 3 Terminated96 enrolled 22 charts
NCT01539291 2019-08-20Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)Gilead SciencesPhase 3 Terminated161 enrolled 34 charts
NCT01659021 2019-08-14Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaGilead SciencesPhase 3 Terminated261 enrolled 21 charts
NCT01980875 2018-11-19Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic LeukemiaGilead SciencesPhase 3 Terminated57 enrolled 12 charts
NCT01980888 2018-11-19Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic LeukemiaGilead SciencesPhase 3 Terminated311 enrolled 12 charts